Lung Adenocarcinoma - Pipeline Insight, 2024

This “Lung Adenocarcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Lung Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lung Adenocarcinoma Understanding

Lung Adenocarcinoma: Overview

Lung adenocarcinoma is the most common primary lung cancer seen in the United States. It falls under the umbrella of non-small cell lung cancer (NSCLC) and has a strong association with previous smoking. While incidence and mortality have declined, it remains the leading cause of cancer death in the United States. Adenocarcinoma of the lung usually evolves from the mucosal glands and represents about 40% of all lung cancers. It is the most common subtype to be diagnosed in people who have never smoked. Lung adenocarcinoma usually occurs in the lung periphery, and in many cases, may be found in scars or areas of chronic inflammation. By far, the main risk factor for any lung cancer, including adenocarcinoma, is smoking tobacco. Due to numerous carcinogens present in tobacco smoke, primary or secondary exposure increases risk proportional to the amount of exposure. Other risk factors include a family history of lung cancer, or occupational exposure to other agents such as silica, asbestos, radon, heavy metals, and diesel fumes, though these are less prevalent. Resultant genetic mutations in the p53 gene are the most frequent cause of tumorigenesis in NSCLC in 52% of cases.

Lung Adenocarcinoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lung Adenocarcinoma pipeline landscape is provided which includes the disease overview and Lung Adenocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Lung Adenocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lung Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Lung Adenocarcinoma.
• In the coming years, the Lung Adenocarcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Lung Adenocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Lung Adenocarcinoma treatment market. Several potential therapies for Lung Adenocarcinoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Lung Adenocarcinoma market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Lung Adenocarcinoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Lung Adenocarcinoma Emerging Drugs Chapters

This segment of the Lung Adenocarcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lung Adenocarcinoma Emerging Drugs

Bemcentinib: BerGenBio Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase (AXL) a promising therapeutic target for serious diseases. In cancer, recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, metastasis, and resistance to therapy. AXL is also known to play an important role in transporting viruses into cells and once in the cell, AXL signaling promotes the engulfment of the virus increasing infectivity. Currently, it is in Phase II stage of clinical trial evaluation to treat patients suffering from Adenocarcinoma ofLung.

Letaplimab (IBI188): Innovent Biologics IBI188 (letaplimab), developed by Innovent Biologics, is a recombinant fully humanized IgG4 monoclonal antibody targeting CD47. CD47 is a transmembrane protein that blocks phagocytosis of macrophage by binding to the signaling regulatory protein (SIRP) on the surface of macrophage, to send a don't eat me signal. After blocking this myeloid checkpoint, IBI188 (letaplimab) enhanced phagocytosis of tumor cells and cross-activated T cells. Preclinical data showed that IBI188 (letaplimab) had clear target, clear mechanism of action and significant efficacy. Phase 1a clinical data showed that the escalation of all the preset doses has completed, with the highest exploratory dose of 30mg/kg QW. No dose-limiting toxicity occurred in each dose group, and IBI188 (letaplimab) was well toleratedgenerally.

Lung Adenocarcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Lung Adenocarcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lung Adenocarcinoma

There are approx. 25+ key companies which are developing the therapies for Lung Adenocarcinoma. The companies which have their Lung Adenocarcinoma drug candidates in the most advanced stage, i.e. phase II include, BerGenBio.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lung Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lung Adenocarcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lung Adenocarcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lung Adenocarcinoma drugs.

Lung Adenocarcinoma Report Insights

• Lung Adenocarcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lung Adenocarcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lung Adenocarcinoma drugs?
• How many Lung Adenocarcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lung Adenocarcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lung Adenocarcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lung Adenocarcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BerGenBio
• Innovent Biologics
• Lantern Pharma Inc.
• Celltrion
• Pionyr Immunotherapeutics Inc.
• Onconova Therapeutics, Inc.
• Pfizer
• Chugai Pharmaceutical
• Novartis Oncology
• Alaunos Therapeutics
• Tmunity Therapeutics
• Imugene Limited
• Hoffmann-La Roche
• Cantargia

Key Products

• Bemcentinib
• IBI188
• LP-300
• CT-16
• PY159
• Rigosertib
• PF-07220060
• RO5126766
• Spartalizumab
• Neoantigen specific TCR-T cell drug
• hu CART-mesocells
• IMU-201
• RXDX-105
• CAN04

This product will be delivered within 1-3 business days.